All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
During the annual meeting of the Society of Hematologic Oncology (SOHO), held in Houston, TX, US, Pau Montesinos, Hospital La Fe, Valencia, ES, discussed the latest data regarding the use of minimal residual disease (MRD) in acute myeloid leukemia (AML).1
Dr Montesinos began by highlighting the unanswered questions about MRD in AML:1
The 2017 European LeukemiaNet (ELN) guidelines categorize patients with AML who are both, in complete remission (CR) and MRD negative (CRMRD-), as a separate response group to those in CR, CR with incomplete hematologic recovery (CRi), morphologic leukemia-free state (MLFS) or partial remission (PR). This distinction has been made because relapse is more likely in patients in CR or CRi with MRD.2 The guidelines recommend MRD to be assessed by the presence of a genetic marker by real time quantitative polymerase chain reaction (RT-qPCR) or by multi-parameter flow cytometry (MFC). The assessment should be done at early time points, such as post-induction and consolidation so that remission status can be determined, and kinetics of disease response can be evaluated. Assessments may also be done beyond consolidation therapy to identify morphologic relapse that may occur.2
In AML, morphologic CR is distinct from active disease (≥5% marrow blasts by morphology). Patients undergoing transplant who are in morphologic CR but who have MRD (CRMRD+) have poorer outcomes compared to those who are CRMRD-. Araki D et al., retrospectively compared the outcomes of patients with AML (N= 359) who underwent allogeneic transplant (allo-transplant) with active disease, to those in CRMRD+ and CRMRD-. In these cases, transplant source was peripheral blood stem cells (PBSCs) or bone marrow (BM) stem cells and MRD was analyzed by 10-color MFC on BM aspirates prior to transplantation. Survival outcomes by MRD status are shown in Table 1.3 This study found:
* Based on multivariate regression model |
|||
|
CRMRD+ |
Active disease |
CRMRD- |
---|---|---|---|
Three-year cumulative relapse estimate |
67% |
65% |
22% |
Three-year PFS |
12% |
13% |
67% |
Three-year OS |
26% |
23% |
73% |
Three-year cumulative incidence of non-relapse mortality (NRM) |
21% |
23% |
11% |
Hazard ratio (HR) for NRM (95% CI, p value)* |
1.37 0.52–3.65 p= 0.53 |
1.27 0.99–1.65 p= 0.065 |
1.72 0.93–3.18 p= 0.083 |
Grade III/IV acute graft-versus-host disease (aGvHD) at 100 days |
17% |
15% |
8% |
Chronic GvHD (cGvHD) at 18-months |
61% |
54% |
60% |
Dr Montesinos explained how the treatment of AML has evolved over time, beginning with a one-size-fits-all chemotherapy approach when AML was believed to be a single entity. Since then, tailored, risk-adapted therapies also using allo-transplant have been developed based on risk stratification of distinct molecular and chromosomal AML subtypes. The future direction of treatment likely lies in the continued investigation of molecular targets, as markers for MRD detection and for the development of targeted therapies.
In a review article by Buccisano et al., the potential prognostic and therapeutic indications of MRD in AML were summarized. The authors explained that MRD assessment is a key measure of response to chemotherapy and it enables clinicians to plan post-remission strategies that are driven by individual risk of relapse. They noted that MRD assessment at the end of consolidation, in combination with pre-treatment cytogenetic information, will assist in determining which patients are suitable for autologous stem cell transplant (ASCT), based on specific risk of relapse rather than availability of an appropriate donor.4
Buccisano et al., also evaluated the outcomes of an MRD-guided prospective high-risk cohort where the decision for ASCT was based on pre-treatment genetic/cytogenetic information and MRD-positivity post-consolidation. Outcomes of the “prospective” cohort were compared to an “historical” high-risk cohort where treatment decisions were not based on risk stratification (Table 2). They showed at a median follow-up of 18 months that survival estimates were superior for the prospective cohort compared to the historical cohort, supporting MRD-guided decision making.4
|
Prospective (n= 21) |
Retrospective (n= 36) |
p value |
---|---|---|---|
OS |
69% |
24% |
0.046 |
Disease-free survival (DFS) |
70% |
20% |
0.00047 |
The HOVON/SAKK AML 42A study evaluated MRD status in BM samples of adult patients with AML (<60 years old) in CR.5 MRD was assessed by flow cytometry, with the absolute numbers of MRD cells/ml determined by multiplying the MRD frequency with white blood cell count (WBC)/ml in the BM.6 To compare flow cytometry MRD assessment with molecular MRD assessment, the authors also assessed MRD by qRT-PCR for the NPM1 mutation, AML1-ETO, and CBFB-MYH1.5
The authors demonstrated that MRD by flow cytometry was an independent prognostic factor for OS and PFS. Table 3 shows the median MRD values at each stage of treatment. Multivariate analysis after cycle two showed that MRD-positive patients had a significantly higher risk of relapse across multiple subgroups (late CR, WBC>100 x 109/L, and intermediate risk vs good risk).5
* MRD percentage was defined as percentage of leukemia-associated phenotype + (LAP+) cells within WBCs, multiplied by correction factor: 100%/percentage of LAP+ blasts at diagnosis |
|||
|
Induction cycle 1 |
Induction cycle 2 |
Consolidation |
---|---|---|---|
Median MRD, %* |
0.04 (0.01–16) |
0.023 (0.01–21) |
0.021 (0.01–9.6) |
The relapse incidence was higher for MRD-positive compared to MRD-negative patients (Table 4). The results confirmed MRD values of >0.1% of WBC after cycle two (when consolidation treatment decisions are made) were associated with a higher risk of relapse. The authors recommended that patients in the intermediate cytogenetic risk group who were MRD-positive with a late CR after cycle two, should be treated as if they were poor risk.5 These results suggest MRD status may be more predictive further along the treatment pathway.1,5
CIR based on MRD status |
MRD-negative patients with relapse, n |
MRD-positive patients with relapse, n |
p value |
---|---|---|---|
After Induction cycle 1 |
29/109 |
25/55 |
0.005 |
After induction cycle 2 |
53/141 |
29/42 |
<0.001 |
Post-consolidation |
23/97 |
16/24 |
<0.001 |
After induction cycle 2 per risk stratification: |
|
|
|
Good |
9/38 |
7/14 |
0.05 |
Intermediate |
36/88 |
14/19 |
<0.001 |
Poor |
8/15 |
8/9 |
0.007 |
San Miguel et al. evaluated MRD in BM samples from patients in morphologic CR following induction (n= 126) who had aberrant phenotypes at diagnosis. They categorized patients into four risk groups (very low, low, intermediate, high) based on MRD level of LAP+ cells as assessed by flow cytometry and evaluated their outcomes (Table 5). It was shown that MRD level influenced the three-year relapse-free survival (p= 0.0001) and OS (p= 0.003) of patients.7
Risk |
Number of LAP+ cells per 106 BM nucleated cells |
N |
Three-year CIR (%) |
---|---|---|---|
Very low |
<10-4 |
8 |
0 |
Low |
10-4–10-3 |
37 |
14 |
Intermediate |
10-3–10-2 |
64 |
50 |
High |
>10-2 |
17 |
84 |
Dr Montesinos then presented currently unpublished data, of 1118 patients in first CR (CR1), who were categorized by local MRD level post-induction (<0.01%, >0.01–0.1%, >0.1%). MRD was detected as per PETHEMA protocols listed above. Both OS and CIR were significantly associated with MRD level (p< 0.001 and p= 0.01 respectively).
However, there was no significant difference in CIR related to cytogenetic risk (Table 6). Additionally, it appears that after allo-transplant and ASCT, the prognostic value of MRD is lost (p= 0.54 and p= 0.38 respectively), indicating MRD status may only be prognostic in patients receiving chemotherapy as post-CR therapy.1
Risk stratification |
N |
N by MRD status <0.01% vs 0.01–0.1% vs >0.1% |
p value |
---|---|---|---|
Cytogenetic risk |
|||
Low |
186 |
86 vs 44 vs 56 |
0.5 |
Intermediate |
669 |
210 vs 164 vs 294 |
0.26 |
High |
143 |
49 vs 25 vs 69 |
0.24 |
Post-CR therapy by post-induction MRD status |
|||
Allo-transplant |
347 |
84 vs 61 vs 174 |
0.54 |
ASCT |
306 |
125 vs 85 vs 95 |
0.38 |
Only chemo |
418 |
146 vs 89 vs 183 |
0.003 |
Little data is available on the impact of MRD in older patients with AML treated with less intensive therapies. The phase III PETHEMA-FLUGAZA trial evaluated the quality of CR by MRD-status after induction and consolidation as a secondary objective in patients with AML (n= 285) aged >65 years. MRD was assessed by MFC.8
OS was similar in patients in CR with detectable MRD (12 months) and patients in PR (13 months) compared to patients with undetectable MRD (21 months, p= 0.12). MRD >0.1% conferred a significantly higher risk of relapse and inferior OS in elderly patients with AML. Dr Paiva, who presented this data at the 60th American Society of Hematology (ASH) annual meeting, stated that the risk of relapse in patients with undetectable MRD is still high and thus innovative approaches are required to maintain MRD-negativity.8
|
FLUGA |
AZA |
p |
---|---|---|---|
CR |
27% |
22% |
0.33 |
≥PR |
4% |
18% |
<0.001 |
MRD-negative |
25% |
15% |
0.38 |
Two-year CIR |
91% |
77% |
0.09 |
Two-year CIR by MRD |
Total cohort |
|
|
MRD+ ≥10-3 |
95% |
HR: 0.45 (95% CI, 0.3–0.7) p< 0.001 |
|
MRD+ ≥10-4 and <10-3 |
74% |
||
MRD- <10-3 |
45% |
Dr Montesinos then showed the treatment pathway of the ongoing HO132 study, which is a randomized study to assess standard remission-induction chemotherapy and post-remission treatment plus/minus lenalidomide in patients aged 18–65 with previously untreated AML.9
Following achievement of a CR/CRi after two cycles of induction therapy, patients in both arms of the study will undergo PBSC mobilization and treatment decisions based on MRD-status, cytogenetics, and patient status:9
MRD will be assessed by flow cytometry (immuno-MRD) and by NPM1 levels (molecular-MRD).
The design protocol for PETHEMA FLOW-2019 was also presented, which is a study of patients who are NPM1/core binding factor (CBF) negative (intermediate risk) and is based on centralized, rather than local, MRD assessment by RT-qPCR. Patients achieving a CR after first induction (Ara-C + IDA) with intermediate cytogenetics will proceed to second induction followed by centralized MRD assessment. Patients with MRD>0.1% will receive allo-transplant, and ≤0.1% will receive further chemotherapy and ASCT.1
Although many trials have confirmed that CR with detectable MRD is not better than partial remission, Dr Montesinos concluded that there is currently no gold standard for the use of MRD in the treatment of AML. To date, MRD has only formed an exploratory endpoint for clinical trials. Currently, Dr Montesinos’s recommendation is to use MRD in well-defined interventional trials and for research purposes.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox